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a b s t r a c t
Neuropeptide S (NPS) has been recently identified as the endogenous ligand of a previously
orphan G-protein-coupled receptor now named NPSR. Both NPS and its receptor are
expressed in the brain, where they modulate different functions. In particular, it has been
demonstrated that intracerebroventricular (i.c.v.) injection of NPS in rodents increases
wakefulness and promotes anxiolytic-like effects. In the present study we used the defen-
sive burying (DB) test in rats to further investigate the action of human NPS (0.1–10 nmol,
i.c.v.) on anxiety-related behaviors. Diazepam (1.5 mg/kg, i.p.) and caffeine (20 mg/kg, i.p.)
were used in parallel experiments as standard anxiolytic and anxiogenic drugs, respectively.
None of the tested drugs produced statistical differences in the latency to contact the probe,
burying behavior latency, number of shocks received or immobility/freezing duration.
Caffeine increased cumulative burying behavior and the buried bedding height in a statis-
tically significant manner thus promoting anxiogenic like effects. Opposite results were
obtained with diazepam that significantly reduced these behavioral parameters. The
anxiolytic-like action of diazepam was mimicked by NPS that reduced cumulative burying
behavior in a dose dependent manner. Collectively, robust anxiolytic-like effects were
recorded in response to NPS in the DB test. These results are of particular interest since
the outcome of this assay is marginally influenced by drug effects on locomotor activity. In
conclusion, we provide further evidence that NPS evokes genuine anxiolytic-like effects in
the rat; therefore NPSR selective agonists areworthy of development as innovative drugs for
the treatment of anxiety disorders.
# 2008 Elsevier Inc. All rights reserved.
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Neuropeptide S (NPS) is a newly identified peptide transmitter
that is involved in the regulation of anxiety and wakefulness
[33]. Reverse pharmacology studies led to the identification of* Corresponding author. Tel.: +39 059 2055370; fax: +39 059 2055376.
E-mail address: giovanni.vitale@unimore.it (G. Vitale).
0196-9781/$ – see front matter # 2008 Elsevier Inc. All rights reserved
doi:10.1016/j.peptides.2008.08.014NPS as the endogenous ligand of the NPS receptor (NPSR), a
former orphan G-protein-coupled receptor [33]. NPS has
strong sequence conservation across mammalian species
[22] and is namedafter a highly conservedN-terminal serine at
position 1. As an agonist of NPSR, NPS produces an increase in.
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phate accumulation [13,33] indicating a coupling with both Gq
and Gs proteins [21].
NPSR is widely expressed throughout the nervous system:
highest levels of the receptor are found in cortex, thalamus,
hypothalamus and amygdala and low levels in the brainstem
while the NPS precursor mRNA is expressed strongly in a few
brain areas including the locus coeruleus (LC) area, the
principle sensory trigeminal nucleus and the lateral parabra-
chial nucleus of the brainstem [33,32].
This pattern of expressionmay be consistentwith a role for
NPS in arousal, regulation of food intake and anxiety [3,27,33].
NPS appears to induce behavioral activation and induce
wakefulness, but at the same time, produces an anxiolytic-
like effect, a paradox sharedalso bynicotine [16]. This suggests
that arousal and stress are not always closely linked indicating
that diverse sets of responses may be involved and different
neurotransmitter systems implicated in these conditions [12].
NPSwas repeatedly shown to produce anxiolytic-like effects in
mice exposed to several different anxiety-predictive para-
digms and increase locomotor activity [33,23,18].
Indeed, centrally administered NPS could produce an
anxiolytic-like profile that was independent of the motor-
activating effects of the peptide [33]. Since hyperlocomotion
may be associated to emotional consequences, particularly in
stressful conditions, the present study was designed to
investigate the effect of NPS with the aim of minimizing its
possible confounding effect on locomotion. For this purpose,
we chose the rat defensive burying (DB) test. This assay
measures fear-like responses of composite nature, generated
by exposure to stressful environmental conditions and is
established for its sensitivity to conventional anxiolytic
tranquilizers and anxiogenic compounds [11].
The DB test had been previously validated [30], under the
present experimental conditions, with prototypical anxiolytic
(i.e. diazepam) and anxiogenic (i.e. caffeine) compounds on
the basis of dose-response curves in anxiety tests [15,14] and
controlled for effects on sensorimotor function (results not
shown). In the current experiments, the timing scheduled in
this behavioral assay in the rat was assessed using the highest
dose of NPS (10 nmol/rat) in preliminary time-effect experi-
ments on the basis of personal and other groups’ [27]
observations. The effects elicited by NPS were compared to
those evoked, under the same experimental conditions, by the
aforementioned reference stimulant and anxiolytic drugs,
caffeine (20 mg/kg, i.p.) and diazepam (1.5 mg/kg, i.p.).
Our hypothesis was to demonstrate a clear cut anxiolytic
effect of NPS using the rat defensive burying test, an assay that
is marginally affected by locomotor changes.2. Materials and methods
2.1. Animals
Fifty-four adult male Wistar rats, weighing 180–200 g (Harlan
Italy, S. Pietro al Natisone, UD, Italy), were housed in
Plexiglas1 cages in groups of three-four in controlled condi-
tions: free access to food (also purchased from Harlan), and
water; 12-h light/dark cycle (lights off at 18:00); temperature,22  1 8C; humidity, 60%. All testing sessions were performed
between 9:00 and 14:00. Ethical guidelines for investigation of
experimental pain in conscious animals were followed, and
procedures were carried out according to EEC ethical regula-
tions for animal research (EEC Council 86/609; D.Lgs. 27/01/
1992, No. 116).
2.2. Drugs
Human NPS (SFRNGVGTGMKKTSFQRAKS) was synthesized
according to published methods [25] using Fmoc/tBu chem-
istry with a SYRO XP multiple peptide synthesizer (Multi-
Syntech, Witten Germany). Crude peptide was purified by
preparative reversed-phase HPLC and the purity checked by
analytical HPLC and mass spectrometry using a matrix-
assisted laser desorption ionization time of flight (Bruker
BioScience, Billerica, MA, USA) and a ESI Micromass ZMD-2000
mass spectrometer (Waters Corporation, MS, USA). All other
substances (diazepam and caffeine) and reagents were
purchased from Sigma Chemical Co. (St Louis, MO, USA).
2.3. Surgery
The rats were randomly divided into groups of eight animals
each. For intracerebroventricular (i.c.v.) injections, stainless-
steel guide cannulae (23 ga) (Plastic One, Roanoke, VA, USA)
were stereotaxically implanted in the right lateral ventricle, to
a depth of 0.5 mm above the ventricle (in mm from the
bregma: AP = 0.8; L = 1.4; V = 3.25), under ketamine plus
xylazine anesthesia (115 + 2 mg/kg, i.p.; Farmaceutici Gellini,
Aprilia, Italy and Bayer, Milan, Italy, respectively) and fixed in
place with acrylic dental cement and one skull screw. A
removable plug was kept in place except during the drug
injections. All i.c.v. injections were in a volume of 5 ml. After
the end of the experiment, rats were i.c.v. injected with 5 ml of
evans blue dye and sacrificed under anesthesia. The correct
placement of the cannulawas ascertained by inspection of dye
diffusion in the right lateral ventricle.
2.4. Experimental procedure
Human NPS 0.1, 1 and 10 nmol/rat, or saline (CTRL) was i.c.v.
injected in a single administration by means of an injector
(1 mm longer than the guide cannula) at an infusion rate of 5 ml
in 10–15 s; the animals were then subjected to the defensive
burying test 15 min later. Other groups of rats were adminis-
tered with diazepam (1.5 mg/kg, i.p.), caffeine (20 mg/kg, i.p.)
both dissolved in sterile saline, or saline (2 ml/kg, i.p.), 30 min
before the behavioral test. Since the comparisons between
i.c.v. and i.p. saline-treated animals demonstrated no differ-
ences in any behavioral measures, these data have been
pooled together and indicated as controls.
2.5. Defensive burying test
A rectangular Plexiglas burying apparatus consisting of an
acrylic cage (27 cm wide  38 cm long and 38 cm high), with
the floor covered with fine sawdust, was used. A continuously
electrified probe consisting ofwireswrappedaroundawooden
dowel was positioned in the apparatus so that it protruded
Table 1 – Effect of increasing doses of NPS (nmol/rat, i.c.v.) on various behavioral parameters displayed by rats in the
defensive burying test; comparison with diazepam (1.5 mg/kg, i.p.) and caffeine (20 mg/kg, i.p.)
Treatment Latency
to first shock (s)
Latency to bury




Saline 25.4  4.1 96.4  15.7 4.1  0.52 500.4  98.3
Diazepam 35.7  6.2 116.1  20.8 5.4  0.76 394.6  93.1
Caffeine 18.3  2.9 84.9  14.4 3.8  0.48 639.6  100.9
NPS 0.1 21.8  5.6 106.6  13.8 4.7  0.47 462.4  94.8
NPS 1 19.2  4.1 88.2  13.9 5.2  0.67 386.7  91.4
NPS 10 26.6  4.8 123.6  14.8 5.6  0.63 354.3  88.2
Values are expressed as mean  S.E.M. for eight rats for each group. NS = P > 0.05 vs. SALINE. One-way ANOVA never reached significance: F(5,
42) = 1.82; P = 0.13 for latencies to contact the probe; F(5, 42) = 0.97; P = 0.45 for burying behavior latencies; F(5, 42) = 1.49; P = 0.21 for the number
of times rats received shocks from contacting the probe and F(5, 42) = 1.22; P = 0.32 for immobility behavior, respectively.
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the chamber. Contact with the probe produced a shock of
1 mA. Bedding in the chamber was approximatively 5.0 cm in
depth. Animals were habituated (3–4 cagemates together) to
the apparatus, in the absence of the shock probe, for 15 min
each day for 4 consecutive days.
On fifth day, rats were tested individually for 30 min with
the electrified probe in place. The height of bedding behind the
probe was measured before testing and at the end of each 30-
min test period and was expressed as the height of bedding
above the 5.0 cm of bedding already placed in the chamber.
Fresh beddingwas placed in the apparatus before testing each
animal. Behavior during the 30-min test period was recorded
and later scored by two independent observers unaware of the
treatments. Behaviors measured were: latency to first contact
with the probe and to be shocked, latency to initiate burying
(defined as pushing bedding material with the snout or
forelimbs forward in the direction of the prod) from first
contact, total number of shocks received, height of buried
bedding and duration of burying behavior over the entire test
period. In particular, latency to contact the probe is an
indicator of potential changes in locomotion or exploratory
activity [9]. Moreover, the latency intended as the time
elapsing from the first shock to the display of the burying
behavior inversely reflects the animal’s reactivity [24] whereas
the cumulative time of burying behavior, as well as the height
of buried material, has been suggested to reflect the rat’s
anxiety levels in a specific manner [20]. Finally, the crouch/
freeze duration (immobile stay at a counter side against the
shock prod) was also counted as behavioral index since itFig. 1 – Effect of diazepam (1.5 mg/kg, i.p.), caffeine (20 mg/kg, i
duration of burying (a) and on the height of buried bedding (b) in
as meanW S.E.M. for eight rats for each group. *P < 0.05 vs. saliindicates a passive form of shock-prod avoidance behavior
associated with fear and anxiety [9].
2.6. Statistical analysis
All values are expressed as mean  S.E.M. of eight animals.
One-way ANOVA followed by Bonferroni post hoc test was
used to analyze the effects of a treatment with increasing
doses of NPS or reference compounds in the defensive burying
test. The level of significance was set at 0.05.3. Results
In the DB, control rats spent about 103 s in covering the probe
with bedding material (burying behavior) after the shock
(corresponding to 5.7% of the total time) with an average
height of buried bedding of 5.5 cm. The mean number of total
electric shocks received during the 30-min experimental trial
was about 4, the latency to be shocked for the first time being
25.4 s; after the first contact with the electrified probe, an
average period of time of 96 s was registered before the
beginning of the burying behavior (see Table 1).
Caffeine administration (20 mg/kg, i.p., 30 min before the
test) produced a significant increase of both the height of
buried bedding (+55% vs. controls) and the duration of burying
behavior (+52% vs. controls) (Fig. 1). No statistical differences
were detected in latency to contact the probe, burying
behavior latency and number of received electric shocks,
indicating that, under our experimental conditions, this drug.p.) or increasing doses of NPS (nmol/rat, i.c.v.), on the
the defensive burying test in the rat. Values are expressed
ne (CTRL) (one-way ANOVA followed by Bonferroni test).
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displayed a non-significant tendency to increase the time
spent in immobility/freezing postures (Table 1).
Diazepam (1.5 mg/kg, i.p., 30 min before the test) produced
opposite results with respect to caffeine, reducing both the
height of the buried material (51% vs. controls) and the
cumulative time of burying behavior (70% vs. controls)
(Fig. 1). Also diazepam was ineffective in producing any
changes in the other parameters investigated, thus not
interfering with the animal reactivity or exploration, at our
dose used (Table 1).
NPS (0.1-1-10 nmol/rat, i.c.v., 15 min before the test) dose-
dependently reduced the height of buried bedding and the
cumulative burying behavior, the lowest effective dose being
1.0 nmol/rat for both parameters (45% and47% vs. controls,
respectively), thus indicating a specific change in indicators
directly reflecting an anxiolytic-like behavior (Fig. 1). On the
other hand there was no significant difference in any other
parameters evaluated (Table 1), confirming, also forNPS, a lack
of alteration in locomotion/exploration or reactivity. Even at
the highest dose used, NPS did not produce any significant
change in immobility/freezing duration even if a slight dose-
dependent decrease was detected. Thus, NPS paralleled the
effects induced by diazepam and produced opposite results
with respect to caffeine on the burying behavior (ANOVA: F(5,
42) = 23.90; P < 0.001; P < 0.05 vs. CTRL in post hoc Bonferroni
test) and height of bedding (ANOVA: F(5, 42) = 20.83; P < 0.001;
P < 0.05 vs. CTRL in post hoc Bonferroni test).4. Discussion
In the present study, we used the DB test in rats for
investigating the effects of NPS on anxiety, in comparison
with diazepam and caffeine as standard anxiolytic and
anxiogenic drugs, respectively. Injections of NPS (i.c.v.)
dose-dependently attenuated burying behavior in the DB test
mimicking the effects of diazepam while caffeine produced
opposite results. Therefore we confirmed and extend previous
findings [33,23,18] to a different species (the rat) and to a
different assay (the DB), demonstrating that supraspinal
administration of NPS produces robust anxiolytic-like effects
that are very consistent among animal species and preclinical
models of anxiety.
In the DB assay, drugs that are clinically effective in the
treatment of anxiety disorders such as benzodiazepines or
selective serotonin reuptake inhibitors dose-dependently
shorten the burying behavior and height of the bedding
material at low shock intensity. Moreover, the drug-class
specificity of this test has been demonstrated [7]. Thus, the DB
test can be regarded as a simple and reliable method to detect
the activity of drugs able to modify anxiety states.
Up to now, no evidence is present in the literature
regarding the effects of caffeine in the DB test in rats.
However, the anxiogenic action of caffeine (10, 25 and
50 mg/kg, i.p.) has been investigated in rats using several
assays [4]. Caffeine produced a dose-related anxiogenic profile
in rodents comparable to that of yohimbine [4]. In our study
caffeine increased the height of buried bedding as well as the
duration of burying behavior thus demonstrating a clearanxiogenic action. The present results regarding the anxiolytic
effect of diazepam in the rat DB test are in line with those
described by other groups [28,31] regarding the ability of
diazepamto inhibit probe burying behavior of rats subjected to
the DB task. At doses higher than those used in the present
study, benzodiazepines produced an increase in burying
behavior latency suggesting that this parameter reveals
changes in animal reactivity [10]. On the contrary, under
our experimental conditions, only parameters specifically
related to anxiety were significantly modified by diazepam
treatment. These differences may be explained by some
features of the test design (intensity of the electric shock,
duration of the behavioral recording, drug dose) and indicate
that our experimental procedure induces less interference on
the animal reactivity either using anxiolytic or anxiogenic
substances. As regards locomotor activity, our data are in line
with authors [15] who demonstrated that diazepam (from 0.5
to 2.0 mg/kg, i.p.) dose-dependently reduced the rat cumula-
tive burying without modifying ambulatory behavior. Higher
doses of diazepam (i.e. 4.0 mg/kg) produced stronger effects on
cumulative burying but also depressed locomotion, indicating
that this dose provoked sedative actions that may bias the
interpretation of the results.
Under the same experimental conditions, the anxiolytic-
like effects of diazepam were mimicked by the supraspinal
administration of NPS. In fact, the peptide in the dose range
of 0.1–10 nmol/rat produced a behaviorally selective inhibi-
tion of cumulative burying behavior and height of buried
material, thus suggesting a reduction of the anxiety state of
the rats. This result confirmed previous findings obtained in
mice by different groups using a rather large panel of assays
[33,23,18]. Interestingly enough, the dose range of activity of
NPS in the present rat experiments (0.1–10 nmol) is very
similar to that reported in mice studies (0.01–1 nmol)
[33,23,18].
In the same range of doses NPS has been reported to
consistently stimulate locomotor activity inmice [33,25,23,18].
This stimulatory effect of NPS which may interfere with the
interpretation of the results obtained in the above-mentioned
assays as well as in the present experiments, seems to be less
robust in rats [27,2]. However, it is unlikely that the decrease in
burying behavior in response toNPS could be someway related
to a general motor activity modification since no changes in
locomotion (latency to contact the probe and burying behavior
latency) were detected, indicating no general alteration in
animal motor activity or reactivity under the present experi-
mental conditions. As a matter of fact, motor activity may be
considered a minor interfering parameter in the outcome of
the DB assay since the main parameter that is predictive of
anxiolysis is the inhibition of an active defensive behavior
(burying) [9]. Indeed, the possible actions of NPS on locomo-
tion, shown in other assays, may affect the DB test in the way
of increasing the duration of the burying behavior rather than
inhibiting it, as it actually happens in our case. Therefore we
propose to interpret the behavioral changes induced by NPS in
the rat DB test as a genuine anxiolytic-like effect. The results
obtained in mice with other assays which are marginally
influenced by locomotion such as the marble burying [33] and
the stress-induced hyperthermia [18,23] corroborate this
proposal.
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strated only a slight anxiolytic-like behavior in alcohol-
preferring animals, detected by an activity cage but non by
the elevated plus maze test (EPM) [2]. The discrepancies
between our and the above-mentioned results could be
explained by the differences in strain and gender, by the
parameters evaluated as well as by the differential sensitiv-
ities of the test.
Indeed, we did prefer to use the DB test instead of themore
commonly used paradigm, the EPM, in the current experi-
ments. In fact, the administration of anxiolytic drugs leads to
the expression of opposite behaviors in these two situations:
in the DB test, a decrease of anxiety is related to a behavioral
inhibition (the rat stops burying the probe) whereas, in the
EPM, a decrease of anxiety corresponds to a behavioral
disinhibition (the rat exits more often in the open arms) [29].
Therefore, the value of the present study resides in the fact
we confirm our hypothesis that NPS promotes a clear cut
anxiolytic effect in rats when possible confounding changes in
locomotion areminimized. Thus, NPS behaves as an important
signal in the brain whose anxiolytic-like effects are similar to
those elicited by diazepam and opposite to those of caffeine.
Indeed, for its highdegree of face and construct validity, the
defensive burying paradigm allows the measurement of
several behavioral indices of fear/anxiety expression and
can give valid information from which to draw reliable
conclusions on the action of putative anxiolytic compounds
such as NPS.
Surprisingly, no differences were found among the various
groups of rats in the duration of immobility/freezing postures
which indicates a different behavioral expression of anxiety
(passive avoidance) and could have been a useful additional
anxiety/fear parameter in this behavioral paradigm, this index
being reciprocally related to the levels of burying [8,9]. On the
other hand, previous studies demonstrated either no change
or a paradoxical increase in immobility score using benzo-
diazepine-like compounds as well as some anxiogenic agents
(i.e. corticotrophin-releasing factor), thus suggesting that
passive and active (burying) coping responses are possibly
affected by different neuronal networks and display distinct
behavioral profiles [9]. Thus, in our case, the defensive burying
active reaction fulfils the major pharmacological and sensi-
tivity criteria to be considered a reliable response to be
assessed for anxiety-related behaviors.
Little is known about the mechanisms by which NPS
promotes its anxiolytic-like action. The expression of the NPS
receptor in several brain regions that are known to be involved
in anxiety [6,26], such as amygdala, thalamus and hypotha-
lamic regions, is consistent with an important role of NPS in
modulating the behavioral response to stress [32].
The receptor mechanism involved in the anxiolytic-like
effects of NPS is also unknown. At this regard, the only
information available up to now in the literature suggests that
selective NPSR activation represents themechanism bywhich
NPS stimulates locomotor activity in mice. In fact, peripheral
administration of the NPSR antagonist SHA 68 (50 mg/kg, i.p.)
is able to antagonizemiceNPS-induced horizontal and vertical
activity [19].
The use of this compound as well as the identification of
otherNPSR selective and potent antagonists, togetherwith thestudy of the phenotype of mice knockout for the NPSR gene [1]
will be of paramount importance, in the near future, for
understanding the roles played by the endogenous NPS-NPSR
system at the CNS level. In particular, the study of the
regulation of various central functions including the response
to stress, anxiety, locomotor activity, arousal and sleep, and
food intake will be of interest for ultimately identifying
therapeutic indications of novel drugs acting as NPSR selective
ligands.
In conclusion, the present findings strongly support the
hypothesis that the activation of NPS receptor acutely
suppresses anxiety-like behavior and support the possibility
that NPSR could provide an interesting target for the
development of innovative drug for the treatment of anxiety.
Indeed, there is a clear need for more effective anxiolytic
pharmacotherapy; in fact, someof the untoward side effects of
classical anxiolytic drugs are associated with dependence,
interaction with alcohol, or sedation [5]. Novel drugs targeting
the NPSR could possibly represent an efficacious treatment for
anxiety without the risk of sedation because of the unique role
played by NPS in mediating both anxiolytic-like activity and
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